Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pralsetinib

FDA-approved product (capsule, oral), marketed as Gavreto.

Registered studies
19
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Pralsetinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Medullary thyroid gland carcinoma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pralsetinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pralsetinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

    NCT04322890 · start 2020-04-16

    Registered record
    Registry ID
    NCT04322890
    Conditions
    Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation
    Interventions
    Osimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib.; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-04-16
    Completion
    2027-12-24
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation +1 more
    InterventionOsimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib. +1 more
    PhasePhase 2
    Registry statusRecruiting

  • A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

    NCT06195228 · start 2020-01-01

    Registered record
    Registry ID
    NCT06195228
    Conditions
    Advanced Thyroid Cancer Patients Who Received Target Therapy
    Interventions
    dabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy; pralsetinib or selpercatinib with or without anti-PD-1 antibdoy; anlotinib or anlotinib plus anti-PD-1 antibody; lenvatinib plus anti-PD-1 antibody; Other Targets: precise treatment based on the target
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2020-01-01
    Completion
    2028-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Thyroid Cancer Patients Who Received Target Therapy
    Interventiondabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy; pralsetinib or selpercatinib with or without anti-PD-1 antibdoy; anlotinib or anlotinib plus anti-PD-1 antibody +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    NCT03037385 · start 2017-03-17

    Registered record
    Registry ID
    NCT03037385
    Conditions
    RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal Disease
    Interventions
    pralsetinib (BLU-667)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-03-17
    Completion
    2024-03-21
    Enrolment
    590

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer +36 more
    Interventionpralsetinib (BLU-667)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

    NCT04204928

    Registered record
    Registry ID
    NCT04204928
    Conditions
    Non-Small Cell Lung Cancer; Medullary Thyroid Cancer
    Interventions
    pralsetinib (BLU-667)
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; Medullary Thyroid Cancer
    Interventionpralsetinib (BLU-667)
    PhaseNot recorded
    Registry statusApproved for marketing